SuperGen Submits First NDA Module for Pancreatic Cancer Drug

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 12 No 2
Volume 12
Issue 2

DUBLIN, California-Super-Gen Inc. has begun submission of a New Drug Application (NDA) for Orathecin, an oral camptothecin, for the treatment of pancreatic cancer patients who are refractory/resistant to available therapies. The submission will occur on a rolling basis and is ex-pected to be completed by the end of the first quarter of 2003. The submission will contain data on more than 2,700 patients treated under Orathecin study protocols, the company said in a news release.

DUBLIN, California—Super-Gen Inc. has begun submission of a New Drug Application (NDA) for Orathecin, an oral camptothecin, for the treatment of pancreatic cancer patients who are refractory/resistant to available therapies. The submission will occur on a rolling basis and is ex-pected to be completed by the end of the first quarter of 2003. The submission will contain data on more than 2,700 patients treated under Orathecin study protocols, the company said in a news release.

Articles in this issue
COX-2 Inhibitors Decrease Toxicity due to Chemotherapy; May Help Arrest Tumor Progression
Some Activity for Gefitinib in Heavily Pretreated Breast Cancer
Brachytherapy Results Similar for Blacks, Whites
Dose-Dense Chemo Ups Survival in Node+ Breast Cancer
MR Spectroscopy IDs Breast Cancers, Node Involvement
ODAC Wants More Data on Expanded Casodex Indication
SuperGen Submits First NDA Module for Pancreatic Cancer Drug
Two Added to ONI’s Oncology Nursing Editorial Advisory Board
Bortezomib Active in Relapsed/Refractory Myeloma
Telomerase Potential Cancer Biomarker
Developing Targeted Therapy More Difficult Than Anticipated
Preoperative Chemoradiotherapy Downsizes 100% of Rectal Tumors in Phase I/II Trial
Fluorouracil/Leucovorin Maintains Leading Role, Results of Three-Drug Regimens Are Pending
Adjuvant Therapy for Rectal Cancer Still Needed in Node-Positive Cases
Adding Bevacizumab to IFL Combination Does Not Significantly Alter IFL Toxicity
Recent Videos
Although small incision surgery may serve as a conduit to deliver PIPAC-MMC, it may confer benefits in the staging and treatment of peritoneal tumors.
Patients with peritoneal metastases were historically associated with limited survival and low consideration for clinical trials.
Prolonging systemic therapy in patients with gastric or gastroesophageal junction cancers may offer better outcomes than radiation therapy.
Advances in perioperative targeted therapies may enable organ preservation and significantly enhance outcomes for patients with gastric cancers.
Combining sotorasib with panitumumab may reduce the burden of disease in patients with KRAS G12C-mutated metastatic colorectal cancer.
Findings from the CodeBreak 300 study have cemented sotorasib/panitumumab as a third-line treatment option for KRAS G12C-mutated colorectal cancer.
Sotorasib plus panitumumab may offer improved survival compared with previously approved treatment options in KRAS G12C-mutated colorectal cancer.
Related Content
A Staged Approach Offers Benefits Without OS Detriment in Appendix Cancers

A Staged Approach Offers Benefits Without OS Detriment in Appendix Cancers

Tim Cortese
April 2nd 2025
Article

Muhammad Talwa Waheed, MD, found that resection after appendectomy should be prioritized in the treatment of patients with appendiceal cancer.

The approval of sotorasib plus panitumumab is a “welcome step” in KRAS G12C-mutated colorectal cancer, according to Marwan G. Fakih, MD.

Sotorasib Combo Approval May Address Novel Therapy Need in KRAS G12C+ CRC

Marwan G. Fakih, MD
February 24th 2025
Podcast

The approval of sotorasib plus panitumumab is a “welcome step” in KRAS G12C-mutated colorectal cancer, according to Marwan G. Fakih, MD.

Local Excision After Chemo Achieves Negative Margins in Rectal Cancer

Local Excision After Chemo Achieves Negative Margins in Rectal Cancer

Tim Cortese
March 31st 2025
Article

A phase 2 trial presented at SSO met its primary end point by achieving negative margins in 79% of patients with node-negative rectal cancer.

A nurse practitioner discussed risk factors, diagnostic challenges, and treatment planning in patients with pancreatic cancers.

Managing Risks, Planning Treatment, & Making Progress in Pancreatic Cancer

Kelley A. Rone, DNP, RN, AGNP-c
December 2nd 2024
Podcast

A nurse practitioner discussed risk factors, diagnostic challenges, and treatment planning in patients with pancreatic cancers.

Next-Generation Test Shows Sensitivity/Specificity in Pancreatic Cancer

Next-Generation Test Shows Sensitivity/Specificity in Pancreatic Cancer

Tim Cortese
March 26th 2025
Article

The blood test showed consistent, strong results in high-risk subgroups such as those with familial history, pancreatic cysts, or diabetes.

Data from the phase 3 CABINET study support the approval of cabozantinib in patients with pancreatic neuroendocrine tumors.

FDA Approves Cabozantinib in Pancreatic/Extra-Pancreatic Neuroendocrine Tumors

Roman Fabbricatore;Ariana Pelosci
March 26th 2025
Article

Data from the phase 3 CABINET study support the approval of cabozantinib in patients with pancreatic and extra-pancreatic neuroendocrine tumors.